- ICH GCP
- Registr klinických studií v USA
- Klinická studie NCT07680959
Combining HD-tDCS and iTBS in Treating Negative Symptoms of Schizophrenia
The Efficacy of Combined HD-tDCS and iTBS in Treating Negative Symptoms of Schizophrenia
Přehled studie
Postavení
Detailní popis
Typ studie
Zápis (Odhadovaný)
Fáze
- Nelze použít
Kontakty a umístění
Studijní místa
-
-
-
Taipei, Tchaj-wan, 114
- Tri-Service General Hospital
-
-
Kritéria účasti
Kritéria způsobilosti
Věk způsobilý ke studiu
- Dospělý
- Starší dospělý
Přijímá zdravé dobrovolníky
Popis
Inclusion Criteria:
- Subjects diagnosed with DSM-5 schizophrenia or schizoaffective disorder;
- With a clinical presentation characterized by predominant negative symptoms, as determined by psychiatric assessment and a score of at least 20 on the Negative Symptoms Subscale of the Positive and Negative Syndrome Scale (PANSS);
- Stable positive and negative symptoms for at least 4 weeks, as documented in medical records and confirmed by clinical judgment and psychiatric interview;
Exclusion Criteria:
- Unstable medical conditions;
- Current psychiatric comorbidity or active substance use disorder (except for tobacco use disorders);
- Contraindications for MRI, tDCS or rTMS;
- Pregnancy or breastfeeding at the time of enrollment;
- History of meningitis, encephalitis, seizures, intracranial neoplasms or surgery, severe head injury or cerebrovascular disease, or a family history of seizures;
- rTMS or tDCS treatment within the past 6 months as well as a history of electroconvulsive therapy (ECT);
- Any skin lesion at the stimulation sites;
- Patients receiving medications that significantly change the seizure threshold;
- A history of suicidal behavior within the past 6 months, or symptom worsening and emergence of suicidal ideation during the screening period.
Studijní plán
Jak je studie koncipována?
Detaily designu
- Primární účel: Léčba
- Přidělení: Randomizované
- Intervenční model: Paralelní přiřazení
- Maskování: Trojnásobný
Zbraně a zásahy
Skupina účastníků / Arm |
Intervence / Léčba |
|---|---|
|
Experimentální: active iTBS followed by active HD-tDCS
During the 3-week intervention phase, patients in this group will receive 2 sessions of active iTBS per working day for 2 weeks (totaling 20 sessions), followed by 2 sessions of active HD-tDCS per working day for 1 week (totaling 10 sessions).
|
The active iTBS sessions will be delivered using the Magstim Rapid2 stimulator.
The iTBS protocol consists of 3-pulse 50-Hz bursts given every 200 ms (at 5 Hz) for 2 s at 8-s intervals for 60 cycles.
A 2-s train of iTBS will be repeated every 10 s for a total of 1800 pulses per session.
The intensity of stimulation will be set at 80% resting motor threshold (RMT).
The target will be the left DLPFC with the coil centered at the MNI coordinate [-38, 44, 26] calculated from T1-weighted MRI.
The active HD-tDCS will be applied by NeuroConn DC Stimulator Plus.
The central anode will be placed over the International 10-20 electrode position F3 and the return peripheral electrodes placed at Fp1, Fz, C3 and F7.
Stimulation session will be applied at an intensity of 2 mA, 8-sec fade in and 5-sec fade out, for 20 min.
During each session, the subject has to perform a computerized working memory task (i.e., 2-back task).
The two times daily sessions will be separated by at least 2 hours.
|
|
Experimentální: sham iTBS followed by active HD-tDCS
During the 3-week intervention phase, patients in this group will receive 2 sessions of sham iTBS per working day for 2 weeks (totaling 20 sessions), followed by 2 sessions of active HD-tDCS per working day for 1 week (totaling 10 sessions).
|
In the sham iTBS condition, the patients receive the same iTBS regimen and exact positioning of the coil but stimulations will be delivered using a commercial identical looking figure 8 sham coil (Magstim D70 Air film sham coil) that can produce a similar sound and sensation.
In the active HD-tDCS condition, stimulation will be applied by a battery-operated device (NeuroConn DC Stimulator Plus) via 5 carbon rubber electrodes (1 cm radius, high-definition 4 × 1 rings configuration).
To target the left DLPFC, the central electrode (anode) will be placed over International 10-20 electrode position F3, with return peripheral electrodes at Fp1, Fz, C3 and F7.
Stimulation will be applied at an intensity of 2 milliamp (mA), 8-sec fade in and 5-sec fade out, for 20 min.
During each session, the subject has to perform a computerized working memory task (i.e., 2-back task).
The two times daily sessions will be separated by at least 2 hours.
|
|
Experimentální: active iTBS followed by sham HD-tDCS
During the 3-week intervention phase, patients in this group will receive 2 sessions of active iTBS per working day for 2 weeks (totaling 20 sessions), followed by 2 sessions of sham HD-tDCS per working day for 1 week (totaling 10 sessions).
|
The active iTBS sessions will be delivered using the Magstim Rapid2 stimulator.
The iTBS protocol consists of 3-pulse 50-Hz bursts given every 200 ms (at 5 Hz) for 2 s at 8-s intervals for 60 cycles.
A 2-s train of iTBS will be repeated every 10 s for a total of 1800 pulses per session.
The intensity of stimulation will be set at 80% resting motor threshold (RMT).
The target is the left DLPFC with the coil centered at the MNI coordinate [-38, 44, 26] calculated from T1-weighted MRI.
In the sham HD-tDCS stimulation, short continuous currents without neuromodulatory effects will be applied to mimic real-stimulation sensations.
Specifically, sham stimulation will deliver 40-sec, 2 mA normal-like stimulation, followed by a tiny current pulse (110 μA over 15 ms) for impedance control taking place every 550 ms for the remaining time.
The other procedure is the same as the active HD-tDCS stimulation.
|
|
Falešný srovnávač: sham iTBS followed by sham HD-tDCS
During the 3-week intervention phase, patients in this group will receive 2 sessions of sham iTBS per working day for 2 weeks (totaling 20 sessions), followed by 2 sessions of sham HD-tDCS per working day for 1 week (totaling 10 sessions).
|
In the sham iTBS condition, patients receive the same iTBS regimen and exact positioning of the coil but stimulations will be delivered using a commercial identical looking figure 8 sham coil (Magstim D70 Air film sham coil) that can produce a similar sound and sensation.
In the sham HD-tDCS condition, short continuous currents without neuromodulatory effects will be applied to mimic real-stimulation sensations.
Specifically, sham stimulation will deliver 40-sec, 2 mA normal-like stimulation, followed by a tiny current pulse (110 μA over 15 ms) for impedance control taking place every 550 ms for the remaining time.
The other procedure is the same as the active HD-tDCS stimulation.
|
Co je měření studie?
Primární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
The change in Positive and Negative Syndrome Scale (PANSS) negative subscale score
Časové okno: Fifteen weeks
|
PANSS is a clinician-administered rating scale to measure the severity of psychopathological symptoms of the patients with schizophrenia spectrum disorder. The patient is rated from 1 to 7 on 30 different symptom items. All items scores are summed up to yield a total PANSS score, which ranges from 30 to 210. A higher score indicates greater psychopathological symptom severity. PANSS negative subscale has 7 items with its score ranging from 7 to 49. The changes in the PANSS negative subscale score immediately after the 3-week intervention (primary endpoint), as well as at one-month and three-month follow-ups, will be collected as the primary outcome. |
Fifteen weeks
|
Sekundární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
The change in score of the Scale for the Assessment of Negative Symptoms (SANS)
Časové okno: Fifteen weeks
|
The Scale for the Assessment of Negative Symptoms (SANS) is used to assess negative symptoms in schizophrenia on a 25 item, 6-point scale.
The SANS measures five domains of the negative symptoms including affective flattening or blunting, alogia, avolition - apathy, anhedonia - Asociality, Attention.
In each domain, separate symptoms are rated from 0 (absent) to 5 (severe).
A total SANS score ranges from 0 to 125.
The changes in the SANS score immediately after the 3-week intervention, as well as at one-month and three-month follow-ups, will be collected as the secondary outcome.
|
Fifteen weeks
|
|
The change in score of Calgary Depression Rating Scale for Schizophrenia (CDSS)
Časové okno: Fifteen weeks
|
The participants' depressive symptoms will be measured by Calgary Depression Rating Scale for Schizophrenia (CDSS).
The changes in the CDSS score immediately after the 3-week intervention, as well as at one-month and three-month follow-ups, will be collected as the secondary outcome.
|
Fifteen weeks
|
|
The change in the Personal and Social Performance scale (PSP) score
Časové okno: Fifteen weeks
|
PSP is a clinician-administered rating scale for measuring the psychosocial functioning of the patients with schizophrenia spectrum disorder. The PSP scale measures psychosocial functioning within four domains: socially useful activities, personal and social relationships, self-care, and disturbing and aggressive behavior.The patient is rated from 1 to 6 on each item of the four domains. A higher score indicates greater psychosocial functioning in any of the four domains. The final global score is defined according to a summary instruction table. This scale provides a single, overall rating from 1 to 100, where a higher score represents better personal and social function. The changes in the Personal and Social Performance scale (PSP) score immediately after the 3-week intervention, as well as at one-month and three-month follow-ups, will be collected as the secondary outcome. |
Fifteen weeks
|
|
The change in the score of the Beck Cognitive Insight Scale (BCIS)
Časové okno: Fifteen weeks
|
Cognitive insight was measured by the Taiwanese version of the Beck Cognitive Insight Scale (BCIS), a self-reported instrument comprising 15 items.The Taiwanese BCIS is composed of 2 subscales including reflective attitude (9 items) and certain attitude (6 items).
We obtained a R-C (reflective attitude minus certain attitude) index of the Taiwanese BCIS, representing the measurement of cognitive insight by subtracting the score of the certain attitude subscale from that of the reflective attitude subscale.
Lower R-C index scores indicate poorer cognitive insight.
The changes in the score of the Beck Cognitive Insight Scale (BCIS) immediately after the 3-week intervention, as well as at one-month and three-month follow-ups, will be collected as the secondary outcome.
|
Fifteen weeks
|
|
The change in the score of Schizophrenia Quality of Life Scale Revision Four (SQOLR4)
Časové okno: Fifteen weeks
|
The Chinese version of the Schizophrenia Quality of Life Scale Revision Four (SQOLR4) is a self-administered questionnaire of 33 items in two domains: psychosocial and vitality. All but four items are coded on a scale of 0-4 according to the frequency of occurrence during the previous 7 days (0 = always, 4 = never; the four exceptions are coded 0 = never, 4 = always). A higher score indicates higher health-related QoL. The changes in the score of Schizophrenia Quality of Life Scale Revision Four (SQOLR4) immediately after the 3-week intervention, as well as at one-month and three-month follow-ups, will be collected as the secondary outcome. |
Fifteen weeks
|
|
The changes in the results of the Tower of London Drexel University Test 2nd Edition
Časové okno: Three weeks
|
The Tower of London Drexel University Test 2nd Edition is a neuropsychological test for the assessment of executive functioning specifically to detect deficits in planning, which may occur due to a variety of medical and neuropsychiatric conditions.
The changes in the results of the Tower of London Drexel University Test 2nd Edition immediately after the 3-week intervention will be collected as the secondary outcome.
|
Three weeks
|
|
The changes in the results of the Color Trails Test (CTT)
Časové okno: Three weeks
|
The CTT, a culture-neutral version of the Trail Making Test, was selected to measure sustained visual attention.
The CTT consists of two parts (CTT-1 and CTT-2).
The CTT-1 requires participants to connect a series of numbered circles that are randomly printed on a sheet of paper.
In the CTT-2, numbered circles of 1 to 25 are shown twice (printed in pink and in yellow) randomly on a sheet of paper.
Participants are asked to connect the numbers from 1 to 25 alternating between the two colors.
The changes in the results of the Color Trails Test (CTT) immediately after the 3-week intervention will be collected as the secondary outcome.
|
Three weeks
|
|
The changes in the results of the Stroop Color Word Test (SCWT)
Časové okno: Three weeks
|
Stroop Color Word Test (SCWT) will be administered to measure selective attention and cognitive flexibility.
SCWT is composed of three parts, each lasting for 45 seconds.
The changes in the results of the Stroop Color Word Test (SCWT) immediately after the 3-week intervention will be collected as the secondary outcome.
|
Three weeks
|
|
The changes in indices of heart rate variability (HRV)
Časové okno: Three weeks
|
HRV indices represent autonomic functioning. ECG electrodes will be placed on bilateral arms just below the elbows, with a ground electrode placed just above the right wrist bone. Lead I electrocardiogram of each patient will be taken for 5 min after sitting and having a rest for 20 min in a soundproof, dim-lighted room with thermostatic control. The ECG signals will be acquired, stored, pre-processed according to the recommended procedures and processed by an HRV analyser. The time domain of HRV is obtained: Standard deviation of NN intervals (SDNN). Power spectrum of HRV is quantified into the standard frequency-domain measurements including low-frequency power (LF, 0.04-0.15 Hz), high-frequency power (HF, 0.15- 0.40 Hz). The changes in indices of heart rate variability (HRV) immediately after the 3-week intervention will be collected as the secondary outcome. |
Three weeks
|
|
The changes in resting-state EEG features
Časové okno: Three weeks
|
In a dimly lit, electrically shielded room, patients' electroencephalogram (EEG) will be recorded.
Resting-state EEG will be collected with eye opened (5min) and closed (5min).
Signals will be amplified by using EEG amplifiers and stored for offline analyses.
The changes in resting-state EEG features immediately after the 3-week intervention will be collected as the secondary outcome.
|
Three weeks
|
|
The changes in fNIRS features
Časové okno: Three weeks
|
Functional near infrared spectroscopy (fNIRS) system is used to measure the relative changes in oxyhemoglobin (Hb) of the frontal regions.
Resting-state fNIRS fo 180s and verbal fluency task (VFT)-based fNIRS for 160s will be collected in a quiet room.
The changes in fNIRS features immediately after the 3-week intervention will be collected as the secondary outcome.
|
Three weeks
|
|
The changes in resting-state fMRI features
Časové okno: Three weeks
|
Magnetic Resonance Imaging (MRI) scans will be performed on the hybrid 3.0T PET-MR imaging unit (GE Healthcare, Waukesha, WI).
MRI scans will be carried out using the same imaging protocol, including T1-weighted images and resting-state functional MRI (rs-fMRIs).The changes in resting-state fMRI features immediately after the 3-week intervention will be collected as the secondary outcome.
|
Three weeks
|
Spolupracovníci a vyšetřovatelé
Spolupracovníci
Vyšetřovatelé
- Vrchní vyšetřovatel: Hsin-An Chang, M.D., Tri-Service General Hospital (TSGH)
Publikace a užitečné odkazy
Obecné publikace
- Kishi T, Ikuta T, Sakuma K, Hamanaka S, Nishii Y, Hatano M, Kito S, Iwata N. Theta Burst Stimulation Protocols for Schizophrenia: A Systematic Review and Network Meta-Analysis. JAMA Netw Open. 2024 Oct 1;7(10):e2441159. doi: 10.1001/jamanetworkopen.2024.41159.
- Tong S, Chen S, Chen J, Tong Z, Li W, Liu S, Shi H, Yao L, Zhang C, Zhang X. Efficacy and long-term effects of intermittent theta burst stimulation on negative symptoms in schizophrenia: a systematic review and meta-analysis. Brain Commun. 2026 Jan 29;8(1):fcag027. doi: 10.1093/braincomms/fcag027. eCollection 2026.
- Gupta R, Sharma A, Goyal N. Breaking the Negative Symptom Barrier: A Novel Neuromodulation Strategy Using HD-tDCS Primed iTBS in Schizophrenia. J ECT. 2026 Jan 20. doi: 10.1097/YCT.0000000000001224. Online ahead of print.
- Ma CC, Lin YY, Chung YA, Park SY, Huang CC, Chang WC, Chang HA. The two-back task leads to activity in the left dorsolateral prefrontal cortex in schizophrenia patients with predominant negative symptoms: a fNIRS study and its implication for tDCS. Exp Brain Res. 2024 Mar;242(3):585-597. doi: 10.1007/s00221-023-06769-5. Epub 2024 Jan 16.
- Yeh TC, Lin YY, Tzeng NS, Kao YC, Chung YA, Chang CC, Fang HW, Chang HA. Effects of online high-definition transcranial direct current stimulation over left dorsolateral prefrontal cortex on predominant negative symptoms and EEG functional connectivity in patients with schizophrenia: a randomized, double-blind, controlled trial. Psychiatry Clin Neurosci. 2025 Jan;79(1):2-11. doi: 10.1111/pcn.13745. Epub 2024 Sep 24.
- Lin CE, Chen LF, Sack AT, Chang HA. Task-based fNIRS biomarkers of HD-tDCS treatment for negative symptoms in schizophrenia. Schizophr Res. 2026 Aug;294:35-43. doi: 10.1016/j.schres.2026.04.010. Epub 2026 Apr 17.
Termíny studijních záznamů
Hlavní termíny studia
Začátek studia (Aktuální)
Primární dokončení (Odhadovaný)
Dokončení studie (Odhadovaný)
Termíny zápisu do studia
První předloženo
První předloženo, které splnilo kritéria kontroly kvality
První zveřejněno (Aktuální)
Aktualizace studijních záznamů
Poslední zveřejněná aktualizace (Aktuální)
Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality
Naposledy ověřeno
Více informací
Termíny související s touto studií
Klíčová slova
Další relevantní podmínky MeSH
Další identifikační čísla studie
- B202303001
Plán pro data jednotlivých účastníků (IPD)
Plánujete sdílet data jednotlivých účastníků (IPD)?
Popis plánu IPD
Informace o lécích a zařízeních, studijní dokumenty
Studuje lékový produkt regulovaný americkým FDA
Studuje produkt zařízení regulovaný americkým úřadem FDA
produkt vyrobený a vyvážený z USA
Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .